Posts

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

on

Alnylam and Tenaya Partner in $1.13B Cardiovascular Gene Target Collaboration

on

SanegeneBio Licenses RNAi Program to Genentech for $200M Upfront and Up to $1.5B in Milestones

on

Arrowhead's RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data

on

SanegeneBio raises over $110M Series B after Lilly RNAi deal

on

Eli Lilly Strikes Multiple Deals for Ultra-Rare Eye Disease Gene Therapy and RNAi Partnerships

on

Aerska Launches with $21M to Use Brain 'Shuttles' for RNAi Delivery in Neurological Diseases

on

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

on

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

on

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

on

Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch

on

Sanofi Acquires China Rights to Arrowhead's Plozasiran for $395 Million

on

Alnylam's Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

on

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

on